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Abstract 
Background: Progressive reduction in renal function results in an increased risk of 
malnutrition.  Despite this, there is little evidence informing the impact of nutrition 
intervention on pre-dialysis chronic kidney disease (CKD, Stage IV and V).   
Study design: Randomized-controlled trial 
Setting and participants: Fifty-six (Male 62%; age mean (SD) 70.7 (14.0) years) CKD 
outpatients,were randomly allocated to intervention (n=29) or control (n=27) by concealed 
computer-generated sequence.   
Intervention: Intervention group were provided with individualized dietary counseling with 
regular follow-up, aimed at achieving an intake of 0.8-1.0g/kg protein and >125kJ/kg energy; 
or control, receiving written material only.  
Outcomes: Body composition, nutritional status and dietary intake 
Measures: Change in body composition (body cell mass, BCM, measured by total body 
potassium, in 40/56 participants), nutritional status (Subjective Global Assessment, SGA) and 
energy and protein intake (three-day food record).  
Results: Over the 12 weeks, the control group lost BCM (-3.3% (95% CI -6.9 to 0.4)), whilst 
the intervention group maintained (0.60% (-2.9 to 4.1)).  The overall difference in change 
between treatment groups for BCM 3.6% (-1.0 to 8.7) and energy intake 17.7kJ/kg/day (8.2 to 
27.2) and improvements in SGA (X2 (2) = 12.76 (P<0.01)), favoring the intervention 
treatment.  A large response to treatment allocation was demonstrated in female participants, 
with little change observed in males for either group.  
Limitations:  Power to detect sex differences, change in BCM and potential bias in 
ascertainment of SGA. 
Conclusions:  Structured nutrition intervention may provide beneficial patient outcomes 
including limiting deterioration in nutritional status and increasing dietary energy intake when 
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compared with control treatment for patients in pre-dialysis. Further investigations are 
warranted to determine the impact of such interventions on body composition.   
Index words: Nutrition intervention; chronic kidney disease; pre-dialysis; randomized-
controlled trial; body cell mass; dietary counseling  
Registered Trial: ACTRN012606000493549
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Introduction 
Malnutrition is present in up to 48% of patients at the time of dialysis initiation1 and is an 
independent and significant predictor of morbidity and mortality.2  In Stage 4 chronic kidney 
disease (CKD) (glomerular filtration rate (eGFR) 15-30 mL/min/1.73m2) the focus of the 
medical treatment shifts to managing metabolic disturbances and preparing patients for renal 
replacement therapy (RRT).3  requiring multidisciplinary care to manage symptoms, treat co-
morbidities and prevent complications 3, including optimising nutritional status.4   
 
Deterioration in nutritional status often predates the onset of RRT.5, 6  Patients with advanced 
CKD who are not receiving nutritional management demonstrate the greatest deterioration in 
nutritional status before RRT initiation7. Considering this, there is a need for careful 
nutritional monitoring and appropriate dietary prescription and implementation of nutritional 
care at this time.8    
 
Studies in severe CKD prior to RRT have focused on dietary prescription, in particular, 
restricting protein to below recommended dietary allowance with an aim to provide better 
metabolic control, and potentially delay the progression to dialysis initiation.  A significant 
number of studies, including four meta-analysis9-13 have investigated this relationship, yet, the 
efficacy of a low-protein diet to retard renal failure progression is conflicting and severely 
restrictive diets have poor compliance.14, 15  It appears there may be no greater benefit of 
restricting protein below what is recommended for healthy adults.16   
 
Implementation of nutrition intervention refers to the type, duration, content and location of 
the nutrition care.   Evidence from the Modification of Diet in Renal Disease (MDRD) study 
demonstrate dietary compliance increases with self-management interventions involving 
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patients with ongoing feedback, monitoring and support.17-19 The National Kidney Foundation 
Kidney Dialysis Outcomes Quality Initiative (K/DOQI) guidelines for nutrition care prior to 
dialysis recommend frequent nutritional counselling and monitoring, especially in patients 
presenting with an inadequate intake and/or signs of malnutrition.8 
 
To the authors knowledge, no controlled trial to date has been published to evaluate the 
effectiveness of implementation, with the aim to optimise nutritional status prior to dialysis, 
by promoting a controlled portion (0.8-1.0 g/kg), high energy (>125kJ/kg) intake.4, 20  The 
purpose of this study was to determine if providing individual nutrition counseling with 
regular telephone follow-up improves body composition, energy intake and nutritional status 
compared with providing written material only.  
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 Methods  
Potential participants were approached upon consecutive entry into a pre-dialysis outpatient 
clinic at the Royal Brisbane and Women’s Hospital.  Eligible participants met the following 
criteria: adult (>18 years); eGFR <30ml/min CKD; not previously seen by a dietitian for 
Stage IV CKD; an absence of communication or intellectual impairment inhibiting their 
ability to undertake the intervention; an absence of malnutrition from a cause other than CKD; 
and not expected require RRT within six months.  Participants were randomly allocated to 
receive either individualised nutritional counselling (intervention group) or written education 
material (control group) via a computer-generated number sequence, concealed to the 
recruiting officer until after baseline assessment. 
 
The intervention, administered by a single dietitian, aimed to provide an individualised 
dietary prescription (including energy (125-146kJ/kg/day), and protein (0.75 - 1.0g/kg/day))4, 
incorporating K/DOQI recommendations to provide intensive nutritional counselling with 
regular monitoring.   The delivery of the intervention was guided by the medical nutrition 
therapy framework from the American Dietetic Association, and followed the structure 
provided in Figure 1.21, 22  The intervention group were provided with an initial individual 
consultation at baseline, of up to 60 minutes duration, followed by telephone consultation, 
commonly 15 to 30 minutes duration, fortnightly for the first month, then monthly. The 
intervention utilised self-management principles: goal setting, menu planning, label reading 
and identification of foods containing protein, sodium etc, depending on requirements.  
Participants in the control group received generic nutrition information tailored for CKD (as 
provided in regular clinical practice). 
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The length of the intervention was 12 weeks following baseline assessment.  No participants 
in either group voluntarily dropped out of the study following receipt of intervention, as per 
CONSORT flowchart in Figure 2. 
 
Ethics approval was granted by the Royal Brisbane and Women’s Hospital and Queensland 
University of Technology Human Research Ethics Committees and informed consent was 
obtained from each participant. The following outcome measures included were collected at 
baseline (week 0) and week 12.  
 
Body composition measurements 
The primary outcome of this study was the assessment of body composition by total body 
potassium counting (TBK), a measure of body cell mass (BCM) the body’s functional 
metabolising tissue.  TBK analysis was performed using a shadow shield whole-body counter 
(Accuscan, Canberra Industries, MA, USA), which requires the participant to lie supine on a 
bed that is moved under three sodium iodide detectors. Two 1100 second scans were 
performed on each participant with all personal metallic objects removed.  The detectors 
count 1.46MeV gamma rays being emitted by the potassium-40 (40K). Background and 
sensitivity checks were completed daily and considered in each measurement. On the basis of 
repeated measurements of phantoms, the precision of TBK values from this apparatus was 
2.3%.  The minimal detectable difference of TBK is 4% 23 is considered to be valuable 
research tool for monitoring progress following nutrition intervention.24   
 
Anticipated change in TBK was used to determine the sample size.  Based on the premise that 
the minimum benefit that nutrition intervention will achieve is TBK maintenance, the control 
group in a previously reported study, demonstrated a reduction in TBK of around 5% (± 5) 
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over 12 weeks in Stage IV CKD (n=12).  The sample size was calculated by comparing the 
two means (TBK maintenance vs. 5% loss).  Based on 0.8 power to detect a significant 
difference (P = 0.05, two-sided), 20 patients were required for each study group. The aim was 
to recruit 60 participants to account for anticipated attrition and missing data. 
 
Potassium is the primary intracellular cation and, as 98% of the body’s potassium is located 
within the BCM,25 it is possible to determine BCM from TBK analysis. BCM was calculated 
from TBK using the equation of Wang et al (2003): BCM (kg) = (TBK (g) x 9.18) / 39.1).26  
The measurement of TBK to estimate BCM has been validated in CKD.27   
 
Nutrition assessment 
Nutrition status was also assessed using Subjective Global Assessment (SGA).  This tool 
provides a comprehensive appraisal of nutrition status assessing change in weight, 
gastrointestinal symptoms (anorexia, nausea, etc), food intake, and functional capacity; and 
physical examination, including subcutaneous fat and muscle stores.28  The SGA global rating 
classifies patients into category A (well nourished), B (moderately, or suspected of being  
malnourished) or C (severely malnourished) and is a well validated tool for diagnosis and 
prognosis of nutrition status in CKD.29  SGA assessment was ascertained by a single assessor, 
who was also the dietitian undertaking the intervention and dietary intake assessment. 
   
Dietary intake 
Dietary intake was assessed using a three-day food record.  The participants were requested to 
estimate or measure all food and fluids consumed for those three days (two weekdays and one 
weekend day).  Food records were verified by the dietitian with visual food models and 
household measures to ensure accuracy.  
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Food records were analysed using FoodWorks (Professional Version 3.02 Xyris Software, 
Brisbane, Australia) a computerized food composition database, based on the Australian 
Nutrient Database (AusNut, Department of Human Services and Health, Canberra). The 
software produced an average nutrient consumption per day by calculating the mean intake 
over the three days of recording.  Mean protein and energy intake was calculated in units per 
kg of ideal body weight (calculated according to Ash et al 2006).4   
 
Biochemistry 
Biochemical analysis including albumin by BromoCresol Purple (normal range = 3.5 – 4.8 
g/dL (35–48 g/L)), C-reactive protein (CRP, high sensitive, normal range 0 – 5 mg/L (0.0–0.5 
g/dL), and creatinine (normal range 0.6 – 1.3 mg/dL (53-115mol/L)) was undertaken at a 
central laboratory.  Estimated GFR was calculated using the abbreviated (4-variable) 
Modification of Diet and Renal Disease (MDRD) equation.30   
 
Statistical analysis was carried out using SPSS Version 13 (SPSS Inc, Chicago, IL, USA) 
with the level of significance set at p<0.05.  The analysis of the effect of the intervention 
proceeded as per treatment allocation, irrespective of how compliant participants were with 
the intervention protocol.  Participants were excluded from the final analysis if they either 
died or moved onto RRT during the 12-week trial period (classed as ‘renal death’ or adverse 
event). 
   
Each outcome measure was converted to a change score (Week 12 – Week 0).  Assessment of 
change in outcomes by treatment group was analysis by analysis of covariance (ANCOVA), 
adjusting for baseline values.  Baseline eGFR, body mass index (BMI), sex and co-
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morbidities were identified as potential confounders and were added to each of the original 
ANCOVA models.  Main effects and interactions were assessed.  The final model only 
included covariates with a significant relationship.   
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Results 
Sixty-six consecutive subjects were considered eligible upon entry into the pre-dialysis clinic 
during the recruitment period from September 2004 to September 2005.  Informed consent 
was provided from 62 subjects (62/66, 94% consent rate), following this, six were excluded 
prior to baseline assessment (see CONSORT flowchart, Figure 2).  Therefore, 56 patients 
(Male 62%; age mean (SD) 70.7 (14.0) years) received either intervention (n=29), or control 
(written material only, n=27).  Data in Table 1 demonstrate there was no significant difference 
between participants allocated to either treatment or control group at baseline.   
 
Of the 56 participants who received allocated intervention, no participants voluntary withdrew 
from the study, however, six were lost to follow-up (four died and two went onto receive 
maintenance dialysis, classed as “renal death” or an adverse event), and nine had missing 
BCM data during the intervention period.  The baseline characteristics of the final sample 
with complete data were compared with participants who had incomplete BCM data, and 
those who reached renal death in Table 2.  As demonstrated in Figure 2, there were more 
participants in the intervention group (5 of 29) experiencing adverse events than the control 
group (1 of 27).    Of those who died, all four were from the intervention group; in three the 
identified cause of death was a cardiovascular event and one from an unknown cause.  One 
from each group commenced dialysis, both due to issues in controlling blood pressure control.  
Of those who completed the intervention period, nine were withdrawn from BCM assessment 
(three from the intervention group, and six from control); four due to voluntary withdrawal 
from TBK and five were too large to comfortably undertake the measure due to size 
limitations of the TBK sensor.    
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The following results are from the analysis of the 50 participants who completed the study 
(intervention n=24, and control n=26).   
 
Table 3 identifies mean change in BCM (absolute (kg) and relative (%)) and intake (energy 
and protein) over the treatment period.  BCM change assessed in 82% (n=41) of the final 50 
participants, showed a reduction in the control group and no significant change in the 
intervention group.  The data was re-analysed with an estimate of BCM maintenance for all 
participants lost to follow-up.  Relative (%) change in BCM persisted to be not statistically 
significant, with similar mean difference in change as demonstrated in Table 3 (unadjusted, 
2.6% (-1.4 to 6.6) p=0.2; adjusted 3.7% (-0.4 to 7.8) p=0.07). 
 
Energy intake significantly increased over the treatment period for the intervention group and 
decreased in the control group, with final intake values of 114.5 ± 25.6 k/kg and 102.7 ± 22.2 
kJ/kg respectively.  Conversely, mean protein intake did not change significantly between 
groups; however, the decrease in protein in the control group alone was significant.  Final 
protein intakes were similar between the groups (intervention 0.98 ± 0.22 g/kg and control 
1.00 ± 0.25 g/kg protein).   
 
 
Most participants maintained their baseline nutrition status according to SGA over the 12-
week treatment period.  In the intervention group, 2 participants malnourished (SGA B) at 
baseline died, and the remaining 5 improved their nutritional status, resulting in no 
malnutrition in the intervention group at week 12.  In contrast, the control group had an 
increase in the proportion malnourished from 2/27 (11%) at baseline, to 6/26 (22%, including 
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1 severely malnourished, SGA C) at week 12.  This difference in change in SGA between the 
2 groups was statistically significant X2 (2) = 12.76 (P<0.01).   
 
Table 4 evaluates clinical variables between treatment groups and change over the treatment 
period.  There was negligible difference in change between groups for CRP, eGFR and 
weight.  The mean difference in change in albumin reached statistical significance, reflecting 
a significant decrease in the control group.  
 
Adjusted estimates for change in BCM and intake are also provided in Table 3.  BCM was 
adjusted for baseline BCM, BMI and sex.  Change in dietary energy and protein intake was 
adjusted for baseline intake, comorbidity and sex.  Therefore, sex was identified as a 
consistent confounding variable in a models for each of the outcome variables (main effect p= 
0.005 for BCM; interaction with treatment p=0.004 for both energy and protein intake).  A 
significant sex interaction was identified for protein and energy intake when the interaction 
term was significant (p=0.004, for both), and remained so when the main effect of sex was 
included in the model and not significant (p=0.4 and p=0.5, respectively). This suggests an 
effect modification influencing the treatment outcomes. A descriptive comparison of response 
to treatment allocation comparing each gender is presented in Figures 3 to 5.  These graphs 
indicate a large magnitude in change for females, in particular, with reductions in control 
group for BCM and energy intake, and negligible change for most outcomes in the males for 
each group. 
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Discussion 
There is little literature to inform nutrition practice in CKD prior to dialysis.  The outcome of 
this study supported the use of individualised self-management nutrition interventions with 
regular monitoring, as previously shown to achieve compliance in pre-dialysis CKD patients 
in the MDRD study. 17-19   However, in this study the benefits of this intervention appeared to 
be restricted to females, with no difference in change following intervention in the males in 
this sample. 
  
Malnutrition results in a reduced body cell mass (BCM) and concomitant expansion of extra 
cellular mass. It is the loss of this metabolically active component of body mass which creates 
the negative effects seen with malnutrition.31, 32  A strength of this study is the use of TBK to 
measure BCM, therefore this measure was not influenced by changes in fluid status or non-
nutritional factors.33  From the BCM data, the metabolically active tissue of the control group 
declined, and that of the intervention group was maintained.  While this difference was not 
statistically significant, it was a clinically significant difference in BCM.  Declines of this 
magnitude in BCM are associated with increased disability (reduced strength, immune and 
pulmonary function) and mortality.34, 35   It is likely that a statistically significant difference 
was not evident due to the fact that the 3.5% mean difference in change observed was less 
than the 5% which the sample size was originally powered to detect.  
 
As with BCM, change in SGA is not a commonly reported outcome measure in the CKD 
literature.  SGA is most commonly used to determine the prevalence and prognostic 
significance of malnutrition.29  In Stage IV and V pre-dialysis, SGA B or C are significant 
independent predictors of poor outcome and related to higher mortality and morbidity.6, 36  
Malnutrition in pre-dialysis appears to be a predictor of progression to dialysis, increased rate 
  16 
of acute hospitalisations and death, independent of GFR.36  Prior to this investigation, only 
one small intervention study (n=11) exists in pre-dialysis using SGA as an outcome measure. 
Patients received three-monthly nutrition intervention, and at 6 months, all well-nourished 
patients maintained nutritional status, and 2 of the 3 malnourished patients were reclassified 
as well-nourished.37  This intervention was not randomised or as intensive as the investigation 
featured in this paper, however, further supports the importance of intervention and follow-up 
to promote at least maintenance of nutritional status in pre-dialysis. 
 
Dietary energy intake appeared to be an important intermediate outcome driving nutritional 
status changes in the treatment groups, as particularly evidenced by change for females in 
Figures 3 and 4.  Sufficient energy and quality protein intake is essential for the maintenance 
of nitrogen balance.38  Although there is some evidence that protein intake >0.8g/kg may 
induce a faster rate of decline in GFR compared with low-protein diet,39 there are clear risks 
with provision of a restricted-protein diet (<0.6g/kg/day) that may include simultaneous 
reduction in energy intake and nutrition status parameters (TBK, weight, albumin etc).40, 41  In 
this study, the intervention promoting sufficient energy intake, whilst controlling protein 
intake, resulted in attenuating declines in nutritional status; a surrogate for potential 
improvements in mortality and morbidity outcomes. 
 
Albumin significantly decreased in the control group and was maintained in the intervention 
group, resulting in a significant mean difference in albumin between the two groups at week 
12.  This magnitude of difference reflects the results of other nutrition support interventions in 
CKD.42, 43  
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In this study, there appeared to be significant effect modification by gender for each of the 
nutrition related outcomes, with no difference between treatment groups for males, while the 
females had a significant difference in change in all variables between groups.   
 
The literature supports that nutritional markers predicting outcome can differ by sex.  
Observational studies, using TBK to monitor nutrition status over a longer period of CKD 
progression indicate a progressive reduction in BCM in females only.44 In the MDRD study, 
GFR correlated with dietary energy intake in women but not in men.45 Disparities have also 
been noted in an investigation to determine sex-specific associations between subjects with 
human immunodeficiency virus characteristics and change in body composition, in response 
to treatment.46, 47  Finally, longitudinal and cross-sectional studies report a greater magnitude 
of change in fat-free mass in females with aging.48, 49  A possibility is that the final phase of 
CKD decline prior to dialysis mimics a fast-track of the natural trajectory of FFM decline.50  
 
Aside from the differences noted in the physiology between genders, the self-management 
focus of the treatment relies on patients self-efficacy and responsibility for their own care. 
Despite men and women reporting similar barriers to compliance with dietary prescription, 
women demonstrate better adherence to diets.51  Studies have indicated that locus of control is 
age-dependant, with older males relying more heavily on chance and other factors, rather than 
themselves for change.52  Females report a strong orientation toward self-management of 
health-care needs and were more likely to instigate behavior change.52  This observed gender 
difference may have implications for practice and requires future research to determine if it is 
a reflection of a ‘true’ response.   
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This study had a number of limitations, which include; the sample size, which was under 
powered to detect statistically a clinically significant change in BCM, short treatment duration 
(12 weeks); exclusion of patients close to dialysis commencement (those who potentially may 
benefit the most from the intervention), and was isolated to a single center.  In addition, there 
is potential bias in the ascertainment of the SGA as it was performed by the same person 
delivering the intervention.    
 
There was missing primary outcome data and adverse events which may have introduced bias.  
However, as demonstrated in Table 2, there appeared to be no systematic bias when 
comparing the baseline characteristics of those who reached renal death, had missing BCM 
data to those who completed the study with full data.  The most notable discrepancy between 
the groups existed for BMI and co morbidities.  BMI was notably higher in the participants 
with no BCM outcome data (29.5  7.6 kg/m2) compared with those with full outcome data 
(26.9  4.3 kg/m2).  This can be partially explained participants with a large waist 
circumference being excluded from the TBK analysis due to size restrictions.    Co morbidity 
index was higher in the group that did not complete the study due to death or dialysis, 
indicating this group was at higher risk of these complications from baseline.  This stage of 
CKD is associated with a 3.2- and 5.9-fold increased risk of death53, and mortality rates close 
to 50% over 5 years54.  Therefore, although the mortality rate in the intervention group in this 
study was high (4/29), it was to be expected in this kind of population. 
 
 
By use of a rigorous design, this study demonstrated structured dietetic intervention may be 
effective in attenuating declines in nutritional status of pre-dialysis CKD patients.  Utilising 
counselling via telephone follow-up limited the logistical barriers of patient contact, therefore 
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improving the ability for this research to be translated into practice.   This study represents a 
foundation for which to build the evidence-base for models of dietetic care in pre-dialysis.  
Further recommendations for future research include conducting a cost-benefit analysis for 
the implementation of this service into pre-dialysis management and investigations into the 
benefit of nutrition intervention on improving body composition. 
Conclusion 
The provision of individual nutrition counseling and regular follow-up, with a focus on 
promoting intake produces beneficial patient outcomes. Declines in body cell mass in uraemia 
may be attenuated or reversed, supporting the development of optimal nutritional status in 
pre-dialysis CKD patients. However, the impact of intervention was significant only for 
females, who demonstrated a poorer response to the control treatment. The potential gender 
difference in response to treatment requires further investigation. 
  20 
Acknowledgements: 
We would like to acknowledge Dr Helen Healy at Director of Renal Medicine and Julie 
Hulcombe, Director of Allied Health at Royal Brisbane and Women’s Hospital, for their in-
kind support and contribution to the study; and Justin Scott (Queensland Institute of Medical 
Research) for statistical support. 
Author Contributions:  KLC was the main author of the manuscript, initiated the study, 
collected the data and carried out the statistical analysis and interpretation.  SA and JDB 
initiated the study, supervised the project, assisted in the statistical analysis and interpretation 
and writing the manuscript.   PSWD assisted in the statistical analysis, interpretation and 
writing of the manuscript. 
 
 
  21 
References  
1. Heimburger O, Qureshi AR, Blaner WS, Berglund L and Stenvinkel P: Hand-grip 
muscle strength, lean body mass, and plasma proteins as markers of nutritional status in 
patients with chronic renal failure close to start of dialysis therapy. Am J Kidney Dis 36: 
1213-1225, 2000 
2. Stenvinkel P, Barany P, Chung SH, Lindholm B and Heimburger O: A comparative 
analysis of nutritional parameters as predictors of outcome in male and female ESRD patients. 
Nephrol Dial Transplant 17: 1266-1274, 2002 
3. Bolton WK: Renal physicians association clinical practice guideline: appropriate 
patient preparation for renal replacement therapy: guideline number 3. J Am Soc Nephrol 14: 
1406-1410, 2003 
4. Ash S, Campbell KL, MacLaughlin H, et al.: Evidence Based Practice Guidelines for 
Nutritional Management of Chronic Kidney Disease. Nutr Diet 63: S35-S45, 2006 
5. Barrett BJ, Parfrey PS, Morgan J, et al.: Prediction of early death in end-stage renal 
disease patients starting dialysis. Am J Kidney Dis 29: 214-222, 1997 
6. Churchill D, Taylor, WD., Keshaviah, PR.: Adequacy of dialysis and nutrition in 
continuous peritoneal dialysis: association with clinical outcomes. Canada-USA (CANUSA) 
Peritoneal Dialysis Study Group. J Am Soc Nephrol 7: 198-207, 1996 
7. Ikizler TA, Greene JH, Wingard RL, Parker RA and Hakim RM: Spontaneous dietary 
protein intake during progression of chronic renal failure. J Am Soc Nephrol 6: 1386-1391, 
1995 
8. National Kidney Foundation: K/DOQI clinical practice guideline for nutrition in 
chronic renal failure. Am J Kidney Dis 39: s1-s140, 2000 
9. Fouque D, Laville M and Boissel JP: Low protein diets for chronic kidney disease in 
non diabetic adults (Cochrane Review). Cochrane Database Syst Rev, 2006 
  22 
10. Fouque D, Wang P, Laville M and Boissel JP: Low protein diets for chronic renal 
failure in non diabetic adults (Cochrane Review). Cochrane Database Syst Rev, 2004 
11. Pedrini MT, Levey AS, Lau J, Chalmers TC and Wang PH: The effect of dietary 
protein restriction on the progression of diabetic and nondiabetic renal diseases: A meta-
analysis. Ann Intern Med 124: 627-632, 1996 
12. Kasiske B, Lakatua J, Ma J and Louis T: A meta-analysis of the effects of dietary 
protein restriction on the rate of decline in renal function. Am J Kidney Dis 31: 954-961, 1998 
13. Fouque D, Laville M, Boissel JP, Chifflet R, Labeeuw M and Zech PY: Controlled 
Low Protein Diets in Chronic Renal-Insufficiency - Metaanalysis. Br Med J 304: 216-220, 
1992 
14. Johnson DW: Dietary protein restriction as a treatment for slowing chronic kidney 
disease progression: The case against. Nephrol 11: 58-62, 2006 
15. Aparicio M, Chauveau P and Combe C: Low protein diets and outcome of renal 
patients. J Nephrol 14: 433-439, 2001 
16. Kellet E, Smith A and Schmerlaib Y: The Australian Guide to Healthy Eating - 
Background information for nutrition educators, Canberra ATC : Commonwealth Department 
of Health and Family Services, 1998 
17. Milas N, Nowalk MP, Akpele L, et al.: Factors Associated with Adherence to the 
Dietary Protein Intervention in the Modification of Diet in Renal Disease Study. J Am Diet 
Assoc 95: 1295-1300, 1995 
18. Gillies BP, Caggiula AW, Chiavacci AT, et al.: Nutrition Intervention Program of the 
Modification of Diet in Renal Disease Study:  A Self-Management Approach. J Am Diet 
Assoc 95: 1288-1294, 1995 
19. Doleck TA, Olson MB, Caggiula AW, et al.: Registered Dietitian Time Requirements 
in the Modification of Diet in Renal Disease Study. J Am Diet Assoc 95: 1307-1312, 1995 
  23 
20. Voss D: The CARI Guidelines: Nutriton and Growth in Kidney Disease. Nephrol 10: 
S177-S203, 2005 
21. American Dietetic Association: Chronic Kidney Disease (non-dialysis) Medical 
Nutrition Therapy Protocol: Medical Nutrition Therapy Evidence-Based Guides for Practice. 
Chicago, American Dietetic Association., 2002 
22. Wiggins K: Guidelines for Nutritional Care of Renal Patients. Renal Dietitians 
Dietetic Practice Group, American Dietetic Association Chicago: American Dietetic 
Association, 2002 
23. Ellis KJ: Human Body Composition: In Vivo Methods. Physiol Rev 80: 649-680, 
2000 
24. Dolson GM, Ellis KJ, Johnson ML and Adrogue HJ: Incidence and consequences of 
total body potassium depletion in chronic hemodialysis patients. Front Biosci 1: 126-132, 
2003 
25. Moore F: Energy and the maintenance of the body cell mass. JPEN J Parenter Enteral 
Nutr 4: 228-260, 1980 
26. Wang Z, Zhu S, Wang J, Pierson RN, Jr and Heymsfield SB: Whole-body skeletal 
muscle mass: development and validation of total-body potassium prediction models. Am J 
Clin Nutr 77: 76-82, 2003 
27. Woodrow G, Oldroyd B, Wright A, et al.: The measurement of total body potassium 
in patients on peritoneal dialysis. Perit Dial Int 21: S163-167, 2001 
28. Ottery F: Patient-Generated Subjective Global Assessment, in McCallum P, Polisena, 
C., (ed): The Clinical Guide to Oncology Nutrition. Chicago, American Dietetic Association, 
2000, pp 11-23 
29. Campbell KL, Ash S, Bauer J and Davies PSW: Critical review of nutrition 
assessment tools to measure malnutrition in chronic kidney disease. Nutr Diet 64: 23-30, 2007 
  24 
30. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N and Roth D: A more accurate 
method to estimate glomerular filtration rate from serum creatinine: a new prediction 
equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130: 461-470, 
1999 
31. Tchekmedyian N, Zahyna D, Halpert C and Heber D: Assessment and maintenance of 
nutrition in older cancer patients. Oncology (Huntingt) 6: 105-111, 1992 
32. Cederholm T, Jagren C and Hellstrom K: Outcome of protein-energy malnutrition in 
elderly medical patients. Am J Med 98: 67-74, 1995 
33. Cohn SH, Vartsky D, Yasumura S, Vaswani AN and Ellis KJ: Indexes of body cell 
mass: nitrogen versus potassium. Am J Physiol Endocrinol Metab 244: E305-310, 1983 
34. Castaneda C, Charnley J, Evans W and Crim M: Elderly women accommodate to a 
low-protein diet with losses of body cell mass, muscle function, and immune response. Am J 
Clin Nutr 62: 30-39, 1995 
35. Arora N and Rochester D: Respiratory muscle strength and maximal voluntary 
ventilation in undernourished patients. Am Rev Respir Dis 126: 5-8, 1982 
36. Lawson JA, Lazarus R and Kelly JJ: Prevalence and prognostic significance of 
malnutrition in chronic renal insufficiency. J Ren Nutr 11: 16-22, 2001 
37. Cliffe M, Bloodworth LL and Jibani MM: Can malnutrition in predialysis patients be 
prevented by dietetic intervention? J Ren Nutr 11: 161-165, 2001 
38. Kopple JD: Dietary protein and energy requirements in ESRD patients. Am J Kidney 
Dis 32: S97-104, 1998 
39. Mandayam S and Mitch WE: Dietary protein restriction benefits patients with chronic 
kidney disease. Nephrol 11: 53-57, 2006 
40. Meloni C, Morosetti M, Suraci C, et al.: Severe dietary protein restriction in overt 
diabetic nephropathy: benefits or risks? J Ren Nutr 12: 96-101, 2002 
  25 
41. Castaneda C, Gordon PL, Uhlin KL, et al.: Resistance training to counteract the 
catabolism of a low-protein diet in patients with chronic renal insufficiency. A randomized, 
controlled trial. Ann Intern Med 135: 965-976, 2001 
42. Leon J, Majerle A, Soinski J, Kushner I, Ohri-Vachaspati P and Sehgal A: Can a 
nutrition intervention improve albumin levels among hemodialysis patients? A pilot study. J 
Ren Nutr 11: 9-15, 2001 
43. Leon JB, Albert JM, Gilchrist G, et al.: Improving albumin levels among hemodialysis 
patients: A community-based randomized controlled trial. Am J Kidney Dis 48: 28-36, 2006 
44. Brennan BL, Letteri JM, Cohn SH and Ellis KJ: Serial measurements of body 
composition and total body mineral content in dialysis and nondialysis patients with renal 
failure. Miner Electrolyte Metab 13: 451-461, 1987 
45. Kopple J, Berg R, Houser H, Steinman T and Teschan P: Nutritional status of patients 
with different levels of chronic renal insufficiency. Modification of Diet in Renal Disease 
(MDRD) Study Group. Kidney Int 27: S184-194, 1989 
46. Visnegarwala F, Raghavan SS, Mullin CM, et al.: Sex differences in the associations 
of HIV disease characteristics and body composition in antiretroviral-naive persons. Am J 
Clin Nutr 82: 850-856, 2005 
47. Kotler DP, Thea DM, Heo M, et al.: Relative influences of sex, race, environment, and 
HIV infection on body composition in adults. Am J Clin Nutr 69: 432-439, 1999 
48. Roubenoff R, Hughes VA, Dallal GE, et al.: The Effect of Gender and Body 
Composition Method on the Apparent Decline in Lean Mass-Adjusted Resting Metabolic 
Rate With Age. J Gerontol A Biol Sci Med Sci 55: M757-760, 2000 
49. Newman AB, Haggerty CL, Goodpaster B, et al.: Strength and Muscle Quality in a 
Well-Functioning Cohort of Older Adults: The Health, Aging and Body Composition Study. J 
Am Geriatr Soc 51: 323-330, 2003 
  26 
50. Kyle U, Genton L, Hans D, Karsegard L, Slosman D and Pichard C: Age-related 
differences in fat-free mass, skeletal muscle, body cell mass and fat mass between 18 and 94 
years. Eur J Clin Nutr 55: 663-672, 2001 
51. Chung ML, Moser DK, Lennie TA, et al.: Gender differences in adherence to the 
sodium-restricted diet in patients with heart failure. J Card Fail 12: 628-634, 2006 
52. Buckelew S, Shutty Jr M, Hewett J, Landon T, Morrow K and Frank R: Health locus 
of control, gender differences and adjustment to persistent pain. Pain 42: 287-294, 1990 
53. Go AS, Chertow GM, Fan DJ, McCulloch CE and Hsu CY: Chronic kidney disease 
and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-
1305, 2004 
54. Keith D, Nichols G, Gullion C, Brown J and Smith D: Longitudinal Follow-up and 
Outcomes Among a Population With Chronic Kidney Disease in a Large Managed Care 
Organization. Arch Intern Med 164: 659-663, 2004 
55. Charlson ME, Pompei P, Ales KL and MacKenzie CR: A new method of classifying 
prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40: 
373-383, 1987 
 
 
  27 
Table 1 Baseline characteristics (mean ± SD) of patients with pre-dialysis CKD randomised to Intervention 
(n=29) or Control (n=27) treatment 
 
Baseline Characteristics Intervention  
(n=29) 
Control  
(n=27) 
p-valuea 
Age 69.5  11.7 70.9  11.6 0.7 
Sex, Male n (%) 17 (58.6) 17 (63.0) 0.8 b 
eGFR (ml/min/1.73m2) 23.1  7.2 21.6  6.1 0.4 
Serum Creatinine (mg/dL) c 2.9  1.0  3.0  0.9 0.7 
BMI (kg/m2) 26.8  4.7 27.6  5.2 0.5 
% weight change in 6 months c -1.8  3.6 -0.3  2.8  0.1 
Charlson co-morbidity index 6.5  1.9 6.7  1.9 0.7 
BCM (kg) 31.6  7.3 32.3  8.1 0.8 
Nutritional status  n (%)   0.2 b 
   SGA A Well nourished  22 (75.9) 24 (88.9)  
   SGA B Moderately malnourished 7 (24.1) 3 (11.1)  
Mean daily protein intake (g/kg) 1.07  0.32 1.17  0.35 0.3 
Mean daily energy intake (kJ/kg) 101.8  23.0 108.5  25.2 0.3 
eGFR = Glomerular Filtration Rate, BMI = Body Mass Index, BCM = Body Cell Mass, SGA = Subjective 
Global Assessment, QOL = Quality of Life 
aIndependent samples t-test,  
bchi-square test for independence 
c To convert GFR in mL/min to mL/s, multiply by 0.01667; serum creatinine in mg/dL to mol/L, multiply by 
88.4 
d from previously measured weight in medical notes   
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Table 2  Comparison of baseline characteristics (mean ± SD) of study participants who completed the 
study with full outcome assessment, missing body cell mass assessment and those reaching 
renal death prior to  in pre-dialysis CKD (n=56)  
 Complete 
outcome data 
(n=41) 
Incomplete 
body cell mass  
(n=9) 
Renal deatha 
during trial 
(n=6) 
p-value 
Treatment group (n (%) in Intervention) 21 (51) 3 (33) 5 (83) 0.1 
Age (mean  SD) 69.7  12.4 69.8  10.0 71.6  10.2 0.4 
Sex % M 64.9 53.8 50.0 0.7 
eGFR (ml/min/1.73m2) a 22.5  5.8 22.7  11.3 20.6  2.5 0.8 
BMI kg/m2 (mean  SD) 26.9  4.3 29.5  7.6 25.6  3.5 0.2 
% weight change in previous 6 months -0.73  3.1 -1.29  4.0 -3.60  3.1 0.3 
Charlson co-morbidity index (mean  SD) 6.2  1.8 7.2  2.0 8.5  1.5 0.02 
Nutritional status, n (%)    0.4 
SGA A Well nourished 36 (88) 6 (67) 4 (67)   
SGA B Moderately malnourished 5 (12) 3 (33) 2 (33)  
Home setting, n (%)    0.4 
Lives with partner 25 (61) 7 (78) 4 (67)  
Lives alone 11 (27)  1(11) 1 (16.5)  
Lives with family or carers 5 (12) 1 (11) 1 (16.5)  
* Renal death = refers to a composite of reaching dialysis or death prior to study close 
eGFR = Glomerular Filtration Rate, BMI = Body Mass Index, BCM = Body Cell Mass, SGA = Subjective 
Global Assessment, QOL = Quality of Life 
a To convert GFR in mL/min to mL/s, multiply by 0.01667 
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Table 3  Impact of nutrition counselling on nutrition-related outcomes, difference in mean change (95% CI) 
between treatment groups (control from intervention), both adjusted and unadjusted values 
 
BCM = Body Cell Mass; BMI = Body Mass Index; CI = Charlson Index55 
 a n=41 
 b (note treatment group*sex interaction p<0.001; main effect of sex, not significant) 
 Change in Intervention 
(n=24)  
Change in Control 
(n=26)  
Mean difference   
mean (95%CI)  
p-value Adj r2 
BCM (%) a      
Unadjusted 2.0 (-1.9 to 5.9) -1.5 (-5.5 to 2.5) 3.5 (-2.1 to 9.1) 0.2 0.01 
Adjusted  (sex; BMI)   0.6 (-2.9 to 4.1)  -3.3 (-6.9 to 0.4)  3.6 (-1.0 to 8.7) 0.1 0.24 
BCM (kg) a      
Unadjusted 0.5 (-0.7 to 1.8) -0.5 (-1.8 to 0.8) 1.1 (-0.7 to 2.9) 0.2 0.01 
Adjusted (sex; BMI)     0.1 (-1.1 to 1.1) -1.2 (-2.3 to -0.0) 1.2 (-0.3 to 2.7) 0.1 0.32 
Energy (kJ/kg)      
Unadjusted 11.4 (4.7 to 18.0) -6.3 (-13.0 to 0.4) 17.7 (8.2 to 27.2) <0.001 0.34 
Adjusted (CI; sex) b 14.2 (7.6 to 20.8) -7.9 (-14.3 to -1.6) 22.1 (12.8 to 31.5) <0.001 0.63 
Protein (g/kg)      
Unadjusted -0.07 (-0.15 to 0.02) -0.11 (-0.19 to -0.03) -0.04 (-0.73 to 0.16) 0.5 0.56 
Adjusted (CI; sex) b  -0.05 (-0.13 to -0.03) -0.13 (-0.21 to -0.05) -0.08 (-0.03 to 0.20) 0.1 0.44 
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Table 4 Change in clinical variables during 12-week randomised controlled intervention in pre-
dialysis CKD by treatment group (intervention n=24, control n=26) 
Clinical variable  
(ideal value) 
 
Intervention n=24 
(mean  sd) 
Control n=26 (mean  
sd) 
Mean difference in 
changea  (95% CI) 
 Week 0 Week 12 Week 0 Week 12  
Weight (kg) 73.516.1 73.815.7 76.918.0 77.420.1 0.14 (-1.3 to 1.6) 
eGFR 
(ml/min/1.73m2) b 
23.47.9 22.96.8 21.76.2 21.47.2 0.30 (-1.75 to 2.34) 
Albumin (g/dL)b 3.90.5 4.00.5 3.90.4 3.70.5 -0.23 (-0.4 to -0.05) c 
C-reactive protein 
(mg/L) b 
6.98.6 5.64.0 8.114.7 17.938.2 -11.16 (-13.02 to 35.35) 
a ANCOVA, change in control – intervention (adjusting for baseline values) 
 b To convert GFR in mL/min to mL/s, multiply by 0.01667; serum albumin in g/dL to g/L, multiply by 10; C-reactive protein in mg/L 
to mg/dL, divide by 10. 
 c p<0.01 
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Legends 
Figure 1 Summarised protocol used in this study for the intervention of pre-dialysis CKD patients 
adapted from ADA intervention protocol  
 
Figure 2: CONSORT flowchart of participant progression through randomized controlled trial of 
nutrition intervention in pre-dialysis CKD patients 
 
Figure 3: Mean change (± 95% CI) in body cell mass (%) following a 12-week randomised controlled 
trial of nutritional counselling, split by sex (n=41);  
Control     Intervention          
 
Figure 4: Mean change (± 95% CI) in energy intake (kJ/kg) following a 12-week randomised controlled 
trial of nutritional counselling, split by sex (n=50);  
Control     Intervention          
 
Figure 5: Mean change (± 95% CI) in protein intake (g/kg) following a 12-week randomised controlled 
trial of nutritional counselling, split by sex (n=50);  
Control     Intervention          
 
 
 
